



British Columbia Securities Commission

2011 BCSECCOM 501

Cease Trade Order

**ALDA Pharmaceuticals Corp.,
InNexus Biotechnology Inc.,
North American Medical Services Inc.,
Papuan Precious Metals Corp.**
(each referred to separately as the Reporting Issuer)

Section 164 of the *Securities Act*, R.S.B.C. 1996, c. 418

- ¶ 1 The Reporting Issuer has not filed:
1. a comparative financial statement for its financial year ended June 30, 2011, as required under Part 4 of National Instrument 51-102 *Continuous Disclosure Obligations* (NI 51-102), and
 2. a Form 51-102F1 *Management's Discussion and Analysis* for the period ended June 30, 2011, as required under Part 5 of NI 51-102
- (the required records).
- ¶ 2 Under section 164(1) of the Act, the Executive Director orders that all trading in the securities of the Reporting Issuer cease until:
1. it files the required records, completed in accordance with the Act and rules, and
 2. the Executive Director makes an order under section 164 of the Act revoking this order as it applies to the Reporting Issuer.
- ¶ 3 Despite this order, a beneficial shareholder of the Reporting Issuer who is not, and was not at the date of this order, an insider or control person of that Reporting Issuer, may sell securities of the Reporting Issuer acquired before the date of this order, if:



1. the sale is made through a market outside Canada,
2. the sale is made through an investment dealer registered in British Columbia, and
3. the investment dealer maintains a record of the details of the sales made under this provision.

¶ 4 November 4, 2011

Allan Lim, CA
Manager
Corporate Finance